The first in the series, Unwind In the Mountains, in partnership with acclaimed DJ Charlie Tee, transports audiences to the breathtaking mountain location of Alpe D’huez in France during Tomorrowland Winter, providing a fresh perspective on how electronic music is adapting and thriving in new forms. Watch here.

SVE 108 Pvt. Ltd. built one of India’s first real estate exhibitions inside that moment. Airport Property Fest 2026 — concluded at the T3 Domestic Departure terminal, Chaudhary Charan Singh International Airport, Lucknow — is among the first property events in Indian history executed beyond security check-in, inside a live airside terminal.

Lucknow airport sees approximately 10,000 departing passengers every single day. Not footfall. Not impressions. Not clicks. Real people — business owners, entrepreneurs, senior executives and high net worth individuals — physically present, security cleared, and completely undistracted. Over four days, that is 40,000 moments of direct access to an audience that premium real estate brands spend enormous budgets trying to reach through conventional channels.

Chaudhary Charan Singh International Airport made this platform possible. Eldeco, Omaxe BeTogether, and Ekana — names that have earned the trust of serious buyers across decades — chose to meet that audience here. Their participation said everything about where premium real estate marketing is heading.

No expo hall. No cold traffic. Just India’s most valuable audience — and the brands worthy of them.

Innovation. Growth. Dreams.

Max Smart Speciality Hospital, Saket, announced the launch of a newly built 400-beds tower designed to deliver world-class healthcare and set new standards in advanced medical care in Delhi-NCR.

The new facility integrates advanced medical technology, intelligent digital systems, and globally benchmarked care standards, strengthening the hospital’s ability to deliver high-quality, patient-centric care while reinforcing its position as a leading destination for both domestic and international patients.

The new tower is expected to significantly enhance the hospital’s capacity to meet rising healthcare demand in Delhi-NCR while also supporting India’s growing international medical value travel sector in line with the government’s ‘Heal in India’ vision. Max Smart Super Speciality Hospital, Saket, is the network hospital of Max Healthcare. With a long-term strategy to build Centres of Excellence and expand its bed capacity to 10,000 over the next four years, Max Healthcare aims to effectively address rising patient volumes and consistently high occupancy levels across its network.

Commenting on the launch, Mr. Abhay Soi, Chairman and Managing Director, Max Healthcare Institute Ltd., said, “This state-of-the-art new facility brings together cutting-edge technology, world-class infrastructure, and the finest Indian clinical talent to deliver exceptional patient care for people across the globe. I am confident that this new facility will help establish Delhi-NCR as the hub for medical value travel. This is in line with the Government’s vision to establish India as the leading destination for medical tourism, supported by the ‘Heal in India’ initiative.”

With the addition of the new tower at Max Hospital, Saket complex will have a total capacity of over 1,160 beds, delivering care across 35+ specialties. The new tower houses over 120 critical care beds, 10 modular operating theatres, and advanced Cath Labs, enabling high-acuity care across disciplines such as Cardiac Sciences, Oncology, Renal Sciences, Neurosciences, Gastroenterology, Paediatrics, Robotic Surgery, and Organ Transplants.

Strengthening its position as a centre of excellence, the hospital is equipped with advanced technologies, including the Da Vinci Xi Surgical Robot and Mako Total Knee Replacement Robot, enabling enhanced precision, minimally invasive procedures, and improved patient outcomes.

Hirohama India successfully hosted the prestigious Miss Sake India 2026 contest at Robata – Kuuraku, Mumbai. crowning Ms. Nishita Yogesh Antarkar from Mumbai as the new cultural ambassador for Japanese sake in India.

The elegant ceremony was graced by distinguished guests, including H.E Mr. Toshihiro Kaneko, Acting Consul General of Japan in Mumbai; Ms. Chisato Tateno, Miss Sake Japan 2025; Ms. Mika Onishii, Chairperson of Miss Sake Association; Ms. Akansha Shrivastava, Miss Sake India 2025; and Ms. Mika Eoka, a renowned sake sommelier also known as “Sake Mom India.”

The event commenced with an insightful introduction by Mr. Kojiro Honda, Co-owner and Founder of Hirohama India Pvt. Ltd. and Kuuraku India Pvt. Ltd., said they are organizing this event in India for the third consecutive year. Also, He emphasized that Miss Sake is not just a competition, but also a platform for cultural exchange between India and Japan.

H.E Mr. Toshihiro Kaneko, the Acting Consul General of Japan, emphasized the cultural similarities between India and Japan, noting that these shared values are deeply rooted in history. In the current scenario, Japan is actively collaborating with India to promote regional development through an environmentally friendly approach.

This was followed by the introduction of seven exceptional finalists competing for the coveted title.

During the event, attendees were introduced to the renowned sake brand Hakutsuru, originating from Kobe—one of Japan’s most celebrated sake-producing regions. Known for its pure water, rich heritage, and exceptional craftsmanship, Hakutsuru is enjoyed in over 50 countries worldwide.

After a rigorous selection process evaluated by a distinguished jury, Ms. Nishita Yogesh Antarkar—a business owner and a certified Visharad Kathak dancer with 16 years of experience and a strong passion for language and cultural exchange—was crowned Miss Sake India 2026 by her predecessor, Akansha Shrivastava.

Ms. Priyanka Sarkar, a chef based in Bangalore, and Ms. Sakshi Khari, a storyteller and Japanese language learner from Delhi, were announced as the runners-up.

In her acceptance speech, Ms. Nishita emphasized that “Sake is not merely an alcoholic beverage; it is culture itself, symbolizing the history and spirit of Japan.” She spoke passionately about the immense beauty and value of Japanese tradition, expressing her commitment to expanding the reach of sake’s charm throughout India expressed her commitment to promoting sake culture across India and encouraging more people to explore this refined beverage. 

Other finalists included Ms. Disha (sales professional), Ms. Salwadi Nandini (marketing professional), Ms. Purva Ninad (project coordinator), and Ms. Shivani Thakur (restaurant management professional specializing in Japanese cuisine).

As Miss Sake India 2026, Nishita will engage in promotional activities across the country and represent India at the Miss Sake Japan Finals to be held in June 2026 in Japan.

For updates on Miss Sake India’s journey and upcoming events promoting Japanese sake culture in India, follow @miss_sake_india on Instagram.

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April.

Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary mechanism that can provide new treatment options for patients, including those who may not respond to immune therapy. Both platforms underscore our mission to deliver breakthrough solutions and enable a new generation of cancer therapeutics for patients.”

Antifolate ADCs, a novel linker-drug platform for targeted therapy with a clearly differentiated mechanism of action (abstract #: 3178/13)
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
Time: 20 April, 2:00 PM – 5:00 PM

Resistance to widely used ADC payloads, such as topoisomerase-I and tubulin inhibitors, is increasing, underscoring the need for differentiated approaches. Byondis has revisited the clinically validated antifolates class and developed a proprietary antifolate linker-drug platform that provides a differentiated and validated mechanism of action with a payload designed to overcome systemic side effects.

The optimized payload demonstrates low- to sub-nanomolar potency, strong inhibition of dihydrofolate reductase (DHFR), and broad in vitro cytotoxicity cell lines. It also shows no interaction with key resistance-associated transporters (BCRP, PGP) and favorable physicochemical properties, supporting GMP-scale manufacturing and ADC compatibility. A glucuronide-based linker enhances therapeutic index while maintaining favorable physicochemical properties, preserving ADC stability and enabling potential dual-payload strategies.

Byondis’ lead antifolate ADC, targeting an undisclosed tumor antigen, has shown strong in vitro activity and achieved robust tumor regressions in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) patient-derived xenograft models, with no significant toxicity at active doses. This differentiated profile supports broad tumor applicability, positioning it for use from first-line therapy through to combination approaches.

Phosphonate antibody-drug conjugates, an innovative, immunostimulatory class of ADCs that drive inside-out activation of Vγ9Vδ2 T cells, enabling selective tumor cell killing (abstract #: 6921/2)
Session Category: Immunology
Session Title: Antibody-Drug Conjugates 2
Time: 22 April, 9:00 AM – 12:00 PM

Addressing a critical need for patients who do not respond to immune therapy, Byondis’ linker-drug platform, ByonBoost™, is engineered to activate Vγ9Vδ2 (γδ) T cells in the tumor microenvironment, enabling targeted delivery with an immunologic antitumor effect and compatibility with single and dual-payload concepts.

Gamma delta (γδ) T cells are potent cytotoxic effectors that eliminate tumor cells independently of MHC presentation and are associated with improved clinical outcomes. However, prior approaches to activate Vγ9Vδ2 T cells have been limited by lack of tumor specificity and short half-life.

To address these limitations, Byondis has developed tumor-targeting phosphonate ADCs that selectively deliver payloads to tumor cells, enabling inside-out activation of Vγ9Vδ2 T cells. These ADCs combine a tumor-associated antigen (TAA)-targeting antibody with a cleavable phosphonate payload and have been successfully applied across multiple targets, including CD123, CD20, TROP2, and HER2. They drive robust and targeted immune activation, inducing cytokine release, degranulation and tumor cell killing in vitro, including in studies where primary patient material was used. In non-human primate models, the lead candidate displayed excellent tolerability with no clinical signs of cytokine release syndrome (CRS), even at high doses.

This modular platform enables the dual mechanisms of action of direct tumor targeting and immune activation while preserving antibody effector function. With broad applicability across tumor types and compatibility with multiple antibodies, it represents a differentiated and scalable approach to targeted immunotherapy.

– END –

About Byondis

Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates.

Byondis’ development portfolio leverages expertise in linker-drug (LD) technology, antibody-drug conjugation and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates and regulatory filings, which are all done in-house.

The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417253206/en/

Vadodara, Apr 17: Ankur Scientific, a global leader in bioenergy and waste-to-energy solutions, has marked its 40th year of operations, signalling a new phase of accelerated growth and innovation in the clean energy sector. Over the past four decades, the company has evolved from pioneering biomass gasification systems to delivering advanced solutions across biochar, waste-to-energy, and emerging areas such as green hydrogen.

With a presence across 60+ countries, Ankur Scientific has executed 1000+ projects, enabling the conversion of 10,000 million tonnes of agricultural and industrial waste into clean energy. Its solutions have contributed to generating 350,000 MW+ of renewable energy while reducing approximately 1.5 million tonnes of CO₂ emissions, reinforcing its role in advancing circular economy and sustainable fuel adoption. The company has recorded 25% growth in over the past 3 years, driven by rising demand for decentralised and renewable energy systems.

Marking the milestone, the company has outlined aggressive expansion plans, targeting 50% growth over the next 3 years, with a strategic focus on scaling its presence across the Middle East, Africa, and Southeast Asia. It is actively expanding its global project pipeline, while increasing investments in next-generation technologies such as green hydrogen, advanced biofuels, and carbon capture solutions. The company is also exploring new avenues such as Asset Ownership and Energy Sales, alongside strengthening its R&D capabilities to support future growth.

As part of its 40th year celebrations, Ankur Scientific hosted its Founder’s Day under the theme “40 Years of Innovation: The Journey So Far,” honouring its founder, Dr. B. C. Jain, and bringing together leadership to reflect on the company’s evolution. The event also featured a showcase of key innovations and upcoming projects.

Beyond business milestones, the company reaffirmed its commitment to social impact through initiatives such as the Ashadeep Street-to-School education program, in collaboration with the Mahavir Foundation Trust, along with its Open Scholarship Program supporting students across schools and colleges.

Speaking on the milestone, Ankur Jain, Managing Director of Ankur Scientific, said “Forty years ago, we began with a simple belief that clean energy could shape a better future. Today, that vision has evolved into a global platform of scalable solutions across bioenergy and waste-to-energy. As we enter our next phase, we are focused on accelerating growth, expanding our global footprint, and investing in next-generation technologies like green hydrogen and advanced biofuels to drive long-term impact.”

The company has established itself as a leading player in the sector, working with globally reputed organisations such as the Bill & Melinda Gates Foundation, the Asian Development Bank, along with national governments and municipal bodies. Building on this foundation, it is now gearing up to launch a first-of-its-kind project in the marine fuel space, introducing innovative solutions aimed at redefining the sector.